-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Bicara Therapeutics, Lowers Price Target to $37

Benzinga·11/10/2026 08:32:24
Listen to the news
BTIG analyst Jeet Mukherjee maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $39 to $37.